选择性雌激素受体调节剂——雷洛昔芬  

Raloxifene—A New Selective Estrogen Receptor Modulator

作　　者：孟娟 孙晓霞 

机构地区：[1]山西省运城市卫生学校,山西运城044000

出　　处：《医学综述》2012年第24期4223-4225,共3页Medical Recapitulate

摘　　要：长期以来,人们注意到性别差异以及两性之间在激素水平的差异,是形成两性之间心血管疾病不同发生率、不同疾病进展乃至不同预后转归的原因。鉴于此,对绝经后女性采用雌激素替代疗法在一定程度上降低了绝经后女性心血管疾病的发生率,并对实际病例也产生一定的治疗作用。但雌激素本身广泛的作用以及由此所引起的高乳腺癌和高子宫内膜癌发生率严重限制了雌激素替代疗法的应用。现代药物研发注重保留雌激素的心血管保护作用,同时去除其不良的刺激组织增生作用,开发了选择性雌激素受体调节剂,并将其应用于雌激素替代疗法,以发挥其对绝经后女性的心血管保护作用。It has been noticed for long that differences between males and females and the level of sex hormones are partly the reasons for the big differences in the incidence,progression and prognosis of cardiovascular system diseases between men and women.Given the above opinion,estrogen replacement treatment（ERT）has been used to prevent and treat cardiovascular system diseases in post-menopausal women,which has shown a certain effect in reducing the incidence and treatment.The use of ERT is restricted by the overall effects of estrogen in many tissues,especially its high rate of incidence of breast-and endometrial-cancer in post-menopausal women,though it actually benefits most post-menopausal women suffering different heart diseases.Modern medicine development focuses on retaining the cardiovascular protective effect of estrogen while eliminating its adverse tissue stimulation effect,and has developed selective estrogen receptor modulators,which have been used in ERT for better comprehensive effect.

关 键 词：雷洛昔芬 选择性雌激素受体调节剂 雌激素替代疗法 

分 类 号：R931.6[医药卫生—生药学]